Morgan Stanley raises target for Regeneron stock to USD 779

Published on 10/09/2026 at 15:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Regeneron stock costs EUR 658.85 on October 9, 2026 after EUR 659.65. Revenue increased 16.70 percent to USD 4.29 billion in the second quarter of 2026.

Key points in brief

Morgan Stanley raised its Regeneron price target from USD 758 to USD 779 on October 7, 2026, while keeping an equal-weight rating.
Regeneron reported USD 4.29 billion in revenue and USD 14.29 adjusted earnings per share for the second quarter of 2026.
Lang & Schwarz quoted Regeneron at EUR 658.85 on October 9, 2026, down 0.12 percent from EUR 659.65.
Regeneron will present 10 cancer and thrombosis abstracts at ESMO 2026 from October 23 to October 27.

Flatlay mit Aktienzertifikat, ISIN-Karte, Pipette und Laborutensilien von oben fotografiert — Regeneron Pharma US75886F1075 kombiniert in einem Flatlay Aktienzertifikat, ISIN-Karte, Pipette sowie kleine Antikörper-Fläschchen übersichtlich, Illustration mit AI erstellt.

Morgan Stanley raised its Regeneron stock price target from USD 758 to USD 779 on October 7, 2026, while keeping an equal-weight rating, according to MarketBeat. Regeneron stock was at EUR 658.85 at Lang & Schwarz on October 9, 2026 at 3:32 p.m. CEST, making the target revision the clearest valuation reference while the company prepares new oncology data.

Three pipeline milestones shape the story

On October 1, 2026, Regeneron expanded its Sanofi alliance with four long-acting antibodies and an upfront payment of USD 1.00 billion, with up to USD 7.00 billion in potential milestones, according to StockTitan. The companies will split future profits from the new programs 50:50, but the milestone value remains dependent on development, regulatory and commercial progress.

Also on October 1, 2026, investigational ubamatamab produced a 73.00 percent objective response rate in 11 patients receiving 800 milligrams of monotherapy, with median progression-free survival of 11 months, according to StockTitan. The small early-stage dataset is clinically notable, while the treatment remains investigational and requires further testing.

On October 6, 2026, Regeneron announced 10 abstracts for the European Society for Medical Oncology Congress, covering skin, lung and ovarian cancers as well as cancer-associated thrombosis, according to Regeneron. The event gives investors a defined clinical-data checkpoint rather than a near-term earnings update.

What does the operating base show?

Regeneron generated USD 4.29 billion of revenue in the second quarter of 2026, up 16.70 percent from the prior-year quarter, and reported USD 14.29 of earnings per share against a USD 10.16 consensus estimate, according to MarketBeat. The revenue increase and earnings comparison provide a stronger commercial base for the pipeline announcements, although early clinical programs do not yet translate directly into sales.

Two dates set the next checkpoints

Regeneron's ESMO presentations are scheduled for October 23 through October 27, 2026, including a late-breaking Phase 3 C-POST presentation on October 25, according to Regeneron. The company is scheduled to report third-quarter 2026 results before US markets open on October 30, 2026, according to StockTitan.

Regeneron stock stays near its annual midpoint

Regeneron stock was trading at EUR 658.85 at Lang & Schwarz on October 9, 2026 at 3:32 p.m. CEST, down 0.12 percent versus the prior close of EUR 659.65. The primary Nasdaq listing showed a USD 741.12 quote at 9:34 a.m. EDT, while the 52-week range was USD 541.00 to USD 859.34 and market capitalization was USD 76.4 billion as of October 9, 2026. The further course of trading is shown by the continuously updated real-time quote of Regeneron stock.